Increase in cetuximab-induced skin rash and hypomagnesemia in patients receiving concomitant treatment with proton pump inhibitors (PPIs): a possible drug interaction?-Reference-Cited by-同舟云学术

Increase in cetuximab-induced skin rash and hypomagnesemia in patients receiving concomitant treatment with proton pump inhibitors (PPIs): a possible drug interaction?

Published:2018-12-13 Issue:3 Volume:83 Page:545-550
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Abu-Amna Mahmoud,Bar-Sela Gil^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/article/10.1007/s00280-018-3758-6/fulltext.html

Reference28 articles.

1. Taieb J, Tabernero J, Mini E, Subtil F, Folprecht G, Van Laethem JL, Thaler J, Bridgewater J, Petersen LN, Blons H, Collette L, Van Cutsem E, Rougier P, Salazar R, Bedenne L, Emile JF, Laurent-Puig P, Lepage C, PETACC-8 Study Investigators (2014) Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. Lancet Oncol 15:862–873. https://doi.org/10.1016/S1470-2045(14)70227-X

2. Lacouture ME, Melosky BL (2007) Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: a dermatology-oncology perspective. Skin Ther Lett 12:1–5

3. Duffy A, Rahma O, Greten TF (2013) Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Study Group. Int J Cancer 132:1718. https://doi.org/10.1002/ijc.27805

4. Zaniboni A, Formica V (2016) The Best. First. Anti-EGFR before anti-VEGF, in the first-line treatment of RAS wild-type metastatic colorectal cancer: from bench to bedside. Cancer Chemother Pharmacol 78:233–244. https://doi.org/10.1007/s00280-016-3032-8

5. Bezabeh S, Mackey AC, Kluetz P, Jappar D, Korvick J (2012) Accumulating evidence for a drug-drug interaction between methotrexate and proton pump inhibitors. Oncologist 17:550–554. https://doi.org/10.1634/theoncologist.2011-0431

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk Evaluation of Proton Pump Inhibitors for Panitumumab-Related Hypomagnesemia in Patients with Metastatic Colorectal Cancer;Biological and Pharmaceutical Bulletin;2024-01-01

2. Thésaurus d’interventions pharmaceutiques associées aux prescriptions injustifiées d’inhibiteurs de la pompe à protons;Annales Pharmaceutiques Françaises;2023-05

3. Acquired Disorders of Hypomagnesemia;Mayo Clinic Proceedings;2023-04

4. Proton Pump Inhibitors and Cancer: Current State of Play;Frontiers in Pharmacology;2022-03-14

5. An overview of diagnosis and management of drug‐induced hypomagnesemia;Pharmacology Research & Perspectives;2021-07-18